mometasone cipla ninasprei, suspensioon
cipla (eu) limited - mometasoon - ninasprei, suspensioon - 50mcg 1annus 140annus 1tk
seffalair spiromax
teva b.v. - fluticasone propionate, salmeterol xinafoate - astma - ravimid hingamisteede obstruktiivsete haiguste, - seffalair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.
mometasone teva ninasprei, suspensioon
teva pharma b.v. - mometasoon - ninasprei, suspensioon - 50mcg 1annus 140annus 1tk; 50mcg 1annus 120annus 1tk; 50mcg 1annus 140annus 3tk
mometasone sanoswiss ninasprei, suspensioon
sanoswiss uab - mometasoon - ninasprei, suspensioon - 50mcg 1mõõtannus 120mõõtannus 1tk; 50mcg 1mõõtannus 60mõõtannus 1tk; 50mcg 1mõõtannus 140mõõtannus 1tk; 50mcg 1mõõtannus 60mõõtannus 3tk; 50mcg 1mõõtannus 140mõõtannus 3tk
mometasone sandoz ninasprei, suspensioon
sandoz pharmaceuticals d.d. - mometasoon - ninasprei, suspensioon - 50mcg 1mõõtannus 140mõõtannus 3tk; 50mcg 1mõõtannus 140mõõtannus 2tk; 50mcg 1mõõtannus 60mõõtannus 1tk; 50mcg 1mõõtannus 120mõõtannus 1tk; 50mcg 1mõõtannus 140mõõtannus 1tk
revinty ellipta
glaxosmithkline (ireland) limited - fluticasone furoaat, vilanterol trifenatate - astma - adrenergia ja muud ravimid obstruktiivsete hingamisteede haiguste raviks - astma indicationrevinty ellipta on näidustatud regulaarne astma ravi täiskasvanutel ja noorukitel vanuses 12 aastat ja vanemad, kui kombinatsiooni kasutamine toote (pikatoimeline beeta-2 agonisti ja inhaleeritava kortikosteroidi) on asjakohane:patsientidel ei ole piisavalt kontrollitud inhaleeritava kortikosteroide ja "nii nagu vaja" sisse hingata lühikese toimeajaga beeta-2 agonistide. copd indicationrevinty ellipta on näidustatud sümptomaatiline ravi täiskasvanud copd koos fev1.
bemrist breezhaler
novartis europharm limited - indacaterol, mometasone furoate - astma - ravimid hingamisteede obstruktiivsete haiguste, - bemrist breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.
atectura breezhaler
novartis europharm limited - indacaterol acetate, mometasone furoate - astma - ravimid hingamisteede obstruktiivsete haiguste, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.
enerzair breezhaler
novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - ravimid hingamisteede obstruktiivsete haiguste, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.
bropair spiromax
teva b.v. - salmeterol xinafoate, fluticasone propionaat - astma - ravimid hingamisteede obstruktiivsete haiguste, - bropair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.